FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed to exclusively distribute Curefini® dermal ointment via a Managed Access Program to worldwide (excluding US) targeted patient groups suffering from an Ultra Rare dermatology disease.
Curefini® is an over-the-counter (OTC) medicinal ointment, approved for marketing in the USA on 16/2/2016 (NDC # 69981-754-01/02) made with safe, high-quality ingredients. Product presentation is a 240ml jar.
According to post marketing data and patients testimonials the innovator’s original patented formula (N” US 7,375,923) has been successful in providing certain degree of DQL for patients with connective tissue disorders resulting in extremely fragile skin that blisters and tears from friction or trauma. One of such skin disorder is Epidermolysis Bullosa (EB), a rare disease for which there is no indicated approved medical cure or treatment. Curefini® dermal ointment works by temporarily protecting injured or exposed skin or mucous membrane surfaces from harmful or annoying stimuli and may provide relief to such surfaces.
Program Contact details
For all inquiries regarding Curefini® dermal ointment, please contact: Rachele Cescutti – Program Manager, Curefini® dermal ointment, Global Access.
Rcescutti@farmamondo.com, Phone: +41 91 6976392
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
About Rev Pharma
Rev Pharma is a US based Pharmaceutical Company dedicated for the research and development of therapies to support patients with Epidermolysis bullosa (EB) – a group of inherited connective tissue diseases that cause blisters in the skin and mucosal membranes, with an incidence of 20 per million newborns in the United States.